## Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Claims**

## What is claimed is:

1. (Original) A compound of formula (I), a pharmaceutically acceptable salt, solvate or derivative thereof:

$$R^3$$

## wherein

either A is S and D is N; or A is N and D is S;

ring E is a saturated, unsaturated or aromatic 5 or 6-membered heterocycle which heterocycle in addition to carbon contains one or more ring-heteroatoms independently selected from nitrogen and oxygen, wherein the heterocycle is optionally substituted on any nitrogen atom where appropriate by one or more groups  $R^{Ea}$  independently selected from  $C_{1-6}$ alkyl and  $C_{1-6}$ alkoxy $C_{1-6}$ alkyl and is optionally substituted on any carbon atom where appropriate by one or more groups  $R^{Eb}$  independently selected from oxo,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy and halo;

X is N or CH;

 $R^2$  is hydrogen,  $C_{1-6}$ alkyl, halo, cyano or perfluoro $C_{1-6}$ alkyl; and  $R^3$  is hydrogen or halo.

2. (Original) A compound according to claim 1 where the benzofused ring system including E is selected from the list: benzimidazol-6-yl, benzoxazol-6-yl, benzoxazol-5-yl, 4H-benzo[1,4]oxazin-3-one-6-yl, benzo[1,3]dioxol-5-yl, benzodioxan-6-yl, quinolin-6-yl and benzotriazol-6-yl.

International Application No. PCT/EP2004/006425 International Filing Date: 14 June 2004

- (Currently Amended) A compound according to any preceding claim <u>claim 1</u> where X is N.
- 4. (Currently Amended) A compound according to any preceding claim 1 where R<sup>2</sup> is hydrogen, C<sub>1.6</sub>alkyl, chloro or fluoro.
- 5. (Original) A compound according to claim 4 where R<sup>2</sup> is hydrogen, methyl, chloro or fluoro.
- 6. (Original) A compound according to claim 5 where R<sup>2</sup> is methyl.
- 7 (Currently Amended) A compound according to any preceding claim claim 1 where R<sup>3</sup> is hydrogen.
- 8. (Currently Amended) A compound according to any one of claims 1 to 3 claim 1 wherein, when X is N, R<sup>2</sup> is methyl.
- 9. (Original) A compound according to claim 8 wherein when X is N and R<sup>2</sup> is methyl, R<sup>3</sup> is H.
- 10. (Currently Amended) A compound according to any of the preceding claims claim 1 selected from:
  - 5-(1-methyl-benzimidazol-6-yl)-4-(6-methylpyridin-2-yl)-1,3-thiazol-2-amine;
  - 4-(benzoxazol-6-yl)-5-(6-methyl-pyridin-2-yl)-1,3-thiazol-2-amine;
  - 5-(1-ethyl-benzimidazol-6-yl)-4-(6-methylpyridin-2-yl)-1,3-thiazol-2-amine;
  - 5-(1-(2-methoxyethyl)-benzimidazol-6-yl)-4-(6-methylpyridin-2-yl)-1,3-thiazol-2-amine;
  - 5-[4-methyl-4H-benzo[1,4]oxazin-3-one-6-yl]-4-(6-methylpyridin-2-yl)-1,3-thiazol-2-amine;
  - 5-[4-ethyl-4H-benzo[1,4]oxazin-3-one-6-yl]-4-(6-methylpyridin-2-yl)-1,3-thiazol-2-amine;
  - 4-(benzo[1,3]dioxol-5-yl)-5-(6-methylpyridin-2-yl)-1,3-thiazol-2-amine;
  - 4-(benzodioxan-6-yl)-5-(pyridin-2-yl)-1,3-thiazol-2-amine;
  - 4-(quinolin-6-yl)-5-(pyridin-2-yl)-1,3-thiazol-2-amine;
  - 4-(1-methyl-benzotriazol-6-yl)-5-(pyridin-2-yl)-1,3-thiazol-2-amine;

International Application No. PCT/EP2004/006425
International Filing Date: 14 June 2004
4-(1-methyl-benzimidazol-6-yl)-5-(6-methylpyridin-2-yl)-1,3-thiazol-2-amine;
and

pharmaceutically acceptable salts, solvates and derivatives thereof.

Claims 11-13 (Cancelled).

- 14. (Currently Amended) A method of treatment or prophylaxis of a disorder selected from chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers (including diabetic ulcers, chronic ulcers, gastric ulcers, and duodenal ulcers), ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component. including, but not limited to kidney fibrosis, lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis, primary biliary cirrhosis, restenosis, retroperitoneal fibrosis, mesenteric fibrosis, endometriosis, keloids, cancer. abnormal bone function, inflammatory disorders, scarring and photoaging, in mammals, which comprises administration to the mammal in need of such treatment, an effective amount of a compound of formula (I) as defined in any one of Claims 1 to 10 claim 1.
- 15. (Currently Amended) A pharmaceutical composition comprising a compound of formula (I) as claimed in any-of claims 1 to 10 claim 1 and a pharmaceutically acceptable diluent or carrier.
- 16. (Currently Amended) A combination of a compound of formula (I) as claimed in any one of claims 1 to 10 claim 1 with an ACE inhibitor or an angiotensin II receptor antagonist.